Affiliation:
1. i3S – Instituto de Investigação e Inovação em Saúde Universidade do Porto Rua Alfredo Allen 208 Porto 4200‐135 Portugal
2. INEB – Instituto de Engenharia Biomédica Universidade do Porto Rua Alfredo Allen 208 Porto 4200‐135 Portugal
3. ICBAS – Instituto de Ciências Biomédicas Abel Salazar Rua Jorge de Viterbo Ferreira 228 Porto 4050‐313 Portugal
4. IUCS‐CESPU ‐ Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde Rua Central de Gandra 1317 4585‐116 Gandra Portugal
Abstract
AbstractBreast cancer appears as the major cause of cancer‐related deaths in women, with more than 2 260 000 cases reported worldwide in 2020, resulting in 684 996 deaths. Triple‐negative breast cancer (TNBC), characterized by the absence of estrogen, progesterone, and human epidermal growth factor type 2 receptors, represents ≈20% of all breast cancers. TNBC has a highly aggressive clinical course and is more prevalent in younger women. The standard therapy for advanced TNBC is chemotherapy, but responses are often short‐lived, with high rate of relapse. The lack of therapeutic targets and the limited therapeutic options confer to individuals suffering from TNBC the poorest prognosis among breast cancer patients, remaining a major clinical challenge. In recent years, advances in cancer nanomedicine provided innovative therapeutic options, as nanoformulations play an important role in overcoming the shortcomings left by conventional therapies: payload degradation and its low solubility, stability, and circulating half‐life, and difficulties regarding biodistribution due to physiological and biological barriers. In this integrative review, the recent advances in the nanomedicine field for TNBC treatment, including the novel nanoparticle‐, exosome‐, and hybrid‐based therapeutic formulations are summarized and their drawbacks and challenges are discussed for future clinical applications.
Funder
Fundação para a Ciência e a Tecnologia
European Regional Development Fund
Subject
Biomaterials,Biotechnology,General Materials Science,General Chemistry
Reference195 articles.
1. Decline in Cardiovascular Mortality
2. GLOBOCAN 2020: New Global Cancer Data 2020 https://www.uicc.org/news/globocan-2020-new-global-cancer-data(accessed: November2022).
3. G.C.O. (GLOBOCAN) Breast 2020 https://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf(accessed: January2022).
4. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
5. Cancer Statistics, 2021
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献